ONIVYDE®
is a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. By blocking the enzyme, cancer cells are prevented from multiplying and eventually die.
PharmaEngine, Inc.
We Race With You
Virtual Pharmaceutical Company Business Model
Latest News
-
2025-08-20
PharmaEngine announces TFDA approval of PEP08 Phase 1 clinical trial for solid tumor cancers
-
2025-07-22
PharmaEngine announces Phase I clinical study of PEP08 has been approved by Australia HREC and acknowledged by Australia TGA
-
2025-04-28
PharmaEngine to present three posters in AACR 2025